CHCraig M. Hales

Craig M. Hales

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Recognitions

Top Cited Scholar (2024)

Craig M. Hales has a total of 210 co-authors. Here are the top co-authors by number of shared publications:

  • Cynthia L. Ogden

    Centers for Disease Control and Prevention, Hyattsville, MD, USA

    7 shared publications
  • Rafael Harpaz

    Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA

    7 shared publications
  • Cynthia L. Ogden

    National Center for Health Statistics Centers for Disease Control and Prevention Hyattsville Maryland USA

    6 shared publications
  • David S. Freedman

    National Center for Chronic Disease Prevention and Health Promotion, US Centers for Disease Control and Prevention, Atlanta, Georgia

    6 shared publications
  • Margaret D. Carroll

    National Center for Health Statistics, US Centers for Disease Control and Prevention, Hyattsville, Maryland

    6 shared publications
  • Cheryl D. Fryar

    National Center for Health Statistics, US Centers for Disease Control and Prevention, Hyattsville, Maryland

    5 shared publications

Latest Publications

  • Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop

    by Lesley H. Curtis, David Arterburn, Sengwee Toh, Jingchuan Guo, Miguel A. Hernán, Esti Iturralde, Ania Jastreboff, Kristina H. Lewis, Jennifer L. Lund, Matthew L. Maciejewski, et al.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped the clinical approach to managing obesity and type 2 diabetes. As approved indications have expanded, use of GLP-1RAs has increased rapidly in the United States. Although randomized trials demonstrate strong efficacy, many questions remain about their optimal use in clinical practice. Real-world data (RWD) from electronic health records, registries, insurance claims, and other sources offer a promising avenue to address these questions. However, concerns about data quality, selection bias, and incomplete ascertainment of medication use and outcomes pose significant challenges to the validity of the resulting evidence. In May 2025, the National Institute of Diabetes and Digestive and Kidney Diseases convened experts from regulatory agencies, payer organizations, and academia to explore these challenges. This second of 2 synopsis articles on the workshop summarizes the discussion around the strengths and limitations of various RWD sources and methodological approaches to strengthen causal inference and generalizability. Presenters highlighted pragmatic clinical trials and target trial emulation as strategies to generate stronger real-world evidence (RWE) that is relevant to both clinical practice and policy. The workshop underscored that careful attention to study design, data limitations, and analytic approach is essential to yield RWE that informs clinicians, patients, payers, and policymakers.


  • Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop

    by David Arterburn, Lesley H. Curtis, Sengwee Toh, Marie C. Bradley, David D’ALessio, Noelia Duchovny, David Hines, Kimberly Narain, Anand Parekh, Asheley Skinner, et al.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity and diabetes management, with rapidly expanding indications and use among U.S. adults. Despite their promise, key questions remain about optimal treatment pathways, long-term safety, effectiveness across diverse populations, adherence, and economic impact. Real-world evidence (RWE) derived from electronic health records, claims, and other data sources could address these gaps, but unique challenges complicate its use, such as inconsistent insurance coverage, high discontinuation rates, medication shortages, compounded formulations, and off-label prescribing. To explore these issues, the National Institute of Diabetes and Digestive and Kidney Diseases convened a workshop in May 2025 with experts from regulatory agencies, guideline committees, payers, and academia. Discussions focused on identifying knowledge gaps in GLP-1RA use, evaluating how RWE informs practice, assessing limitations of real-world data, and strategies to reduce bias in RWE. Presentations emphasized RWE's potential to complement randomized trials by capturing rare adverse events, long-term outcomes, and effectiveness in routine care. However, persistent challenges include data reliability, confounding, and incomplete capture of medication use and outcomes, particularly in pediatric and underserved populations. Coverage decisions remain heterogeneous across Medicare, Medicaid, and private payers and across time, underscoring the need for rigorous cost-benefit analyses. The workshop concluded that robust RWE is essential for developing value-based coverage policies and optimizing GLP-1RA use. Continued investment in high-quality data infrastructure and analytic methods will be critical to inform regulatory, clinical, and economic decisions as utilization expands.


  • High BMI z-Scores from Different Growth References Are Not Comparable: An Example from a Weight Management Trial with an Anti-Obesity Medication in Pubertal Adolescents with Obesity

    by Craig M. Hales, Cynthia L. Ogden, David S. Freedman, Kushal Sahu, Paula M. Hale, Rashmi K. Mamadi, Aaron S. Kelly

    Background: The BMI z-score is a standardized measure of weight status and weight change in children and adolescents. BMI z-scores from various growth references are often considered comparable, and differences among them are underappreciated. Methods: This study reanalyzed data from a weight management clinical study of liraglutide in pubertal adolescents with obesity using growth references from CDC 2000, CDC Extended, World Health Organization (WHO), and International Obesity Task Force. Results: BMI z-score treatment differences varied 2-fold from −0.13 (CDC 2000) to −0.26 (WHO) overall and varied almost 4-fold from −0.05 (CDC 2000) to −0.19 (WHO) among adolescents with high baseline BMI z-score. Conclusions: Depending upon the growth reference used, BMI z-score endpoints can produce highly variable treatment estimates and alter interpretations of clinical meaningfulness. BMI z-scores cited without the associated growth reference cannot be accurately interpreted.


  • Open Access

    CDC Extended BMI-for-Age Percentiles Versus Percent of the 95th Percentile

    by Cynthia L. Ogden, David S. Freedman, Craig M. Hales


  • Body fat differences among US youth aged 8–19 by race and Hispanic origin, 2011–2018

    by Crescent B. Martin, Bryan Stierman, Jack A. Yanovski, Craig M. Hales, Neda Sarafrazi, Cynthia L. Ogden

    Summary: Background: The association between body mass index (BMI) and adiposity differs by race/ethnicity.Objective: To examine differences in adiposity by race/Hispanic origin among US youth and explore how those differences relate to differences in BMI using the most recent national data, including non‐Hispanic Asian youth.Methods: Weight, height and DXA‐derived fat mass index (FMI) and percentage body fat (%BF) from 6923 youth 8–19 years in the National Health and Nutrition Examination Survey (NHANES) 2011–2018 were examined. Age‐adjusted mean BMI, FMI and %BF were reported. Sex‐specific linear regression models predicting %BF and FMI were adjusted for age, BMI category and BMI category*race/Hispanic origin interaction.Results: %BF was highest among Hispanic males (28.2%) and females (35.7%). %BF was lower among non‐Hispanic Black (23.9%) compared with non‐Hispanic White (26.0%) and non‐Hispanic Asian (26.6%) males. There was no difference between non‐Hispanic Black females (32.7%) and non‐Hispanic White (33.2%) or non‐Hispanic Asian (32.7%) females. FMI was higher among Hispanic youth compared with non‐Hispanic White youth. Among youth with underweight/healthy weight, predicted %BF and FMI were lower among non‐Hispanic Black males (−2.8%; −0.5) and females (−2.0%; −0.3), compared with non‐Hispanic White youth, and higher among Hispanic males (0.9%; 0.2) and females (2.0%; 0.5), while %BF but not FMI was higher among non‐Hispanic Asian males (1.3%) and females (1.4%). Among females with obesity, non‐Hispanic Asian females had lower %BF (−2.3%) and FMI (−1.7) than non‐Hispanic White females.Conclusions: Differences in %BF and FMI by race/Hispanic origin were not consistent by BMI category among US youth in 2011–2018.


  • Use of prescription medications associated with weight gain among US adults, 1999‐2018: A nationally representative survey

    by Craig M. Hales, Qiuping Gu, Cynthia L. Ogden, Susan Z. Yanovski

    Objective: This study aimed to evaluate trends in the use of obesogenic medications among adults.Methods: Cross‐sectional data on adults aged ≥20 years are from the 1999 to 2018 National Health and Nutrition Examination Survey (n = 52,340). Obesogenic medications were defined according to the 2015 Endocrine Society guidelines on the pharmacological management of obesity. Weight status was categorized according to BMI. Trends in prior 30‐day use were evaluated.Results: In NHANES 2017‐2018, 20.3% of US adults used an obesogenic medication. Beta‐blockers (9.8%) and antidiabetics (5.7%) were the most common; antipsychotics (1.0%) were the least common. Most common indications were disorders of glucose metabolism, hypertension, neuralgia or neuritis, heart disease, and musculoskeletal pain and/or inflammation. From 1999 to 2018, the proportional use of obesogenic medications increased for anticonvulsants (34.4% to 55.0%) but decreased for antidepressants (32.1% to 18.8%), antidiabetics (82.9% to 52.5%), and beta‐blockers (83.9% to 80.7%). The proportional use of obesogenic medications was not associated with weight status, except for antipsychotics.Conclusions: Use of obesogenic medications was common. Differences in the proportional use of obesogenic medication may reflect changing availability of obesogenic versus nonobesogenic medications over time. The decision to prescribe a nonobesogenic alternative, if one exists, is guided by weighing the risks and benefits of available treatments.


  • A method for calculating BMI z-scores and percentiles above the 95th percentile of the CDC growth charts

    by Rong Wei, Cynthia L. Ogden, Van L. Parsons, David S. Freedman, Craig M. Hales

    The 2000 CDC growth charts are based on national data collected between 1963 and 1994 and include a set of selected percentiles between the 3rd and 97th and LMS parameters that can be used to obtai...


    • 1 May 2019
      • No. 334,p. 1-8

    Prescription Drug Use in the United States, 2015-2016.

    by Cresent B Martin, Craig Hales, Qiuping Gu, Cynthia L Ogden

    Monitoring prescription drug use patterns at the population level (1) can inform research and clinical practice. These patterns may shift over time in response to changing health needs, updated clinical guidelines (2), policy changes, and other factors (1,3). The percentage of the U.S. population that used one or more prescription drugs increased from 1999-2000 through 2007-2008 (4). This report describes prescription drug use by age, sex, and race and Hispanic origin in 2015-2016 and trends over the preceding decade.


    • 1 April 2019
      • No. 123,p. 1-8

    Diabetes and Prediabetes Among Adults in Los Angeles County and the United States, 1999-2006 and 2007-2014.

    by Craig Hales, Margaret D Carroll, Tony Kuo, Paul A Simon

    Objective-This report presents the prevalence of diagnosed diabetes, undiagnosed diabetes, total diabetes, and prediabetes among adults aged 20 and over in Los Angeles County and the United States in 1999-2006 and 2007-2014. The prevalence of diagnosed diabetes, total diabetes, and prediabetes in 2007-2014 are presented by age, sex, and race and Hispanic origin. Methods-Data are from in-home interviews and laboratory testing conducted as part of the National Health and Nutrition Examination Survey (NHANES). Los Angeles County has been selected with certainty in every NHANES cycle since 1999. Sample persons in Los Angeles County were selected and sample weights constructed so that estimates represent the county. Prevalence and 95% confidence intervals for diagnosed, undiagnosed, total diabetes, and prediabetes were estimated using self-reported diagnosis of diabetes, plasma fasting glucose, and hemoglobin A1c. Differences in prevalence were tested between Los Angeles County and the United States, between 1999-2006 and 2007-2014, and among demographic subgroups. Results-The age-adjusted prevalence of total diabetes among adults in Los Angeles County increased from 10.5% in 1999-2006 to 14.4% in 2007-2014. In 2007-2014, 40.2% of adults in Los Angeles County had prediabetes. There were no significant differences in the overall prevalence of diagnosed diabetes, undiagnosed diabetes, total diabetes, or prediabetes between Los Angeles County and the United States in 1999-2006 or 2007-2014. The prevalence of diagnosed diabetes, total diabetes, and prediabetes increased with age in both Los Angeles County and the United States. The prevalence of total diabetes was higher in non-Hispanic black adults, Hispanic adults, and Mexican-American adults than in non-Hispanic white adults in both Los Angeles County and the United States.


  • Top Cited Papers

    Differences in Obesity Prevalence by Demographics and Urbanization in US Children and Adolescents, 2013-2016

    by Cynthia L. Ogden, Cheryl D. Fryar, Craig M. Hales, Margaret D. Carroll, Yutaka Aoki, David S. Freedman

    Importance Differences in childhood obesity by demographics and urbanization have been reported. Objective To present data on obesity and severe obesity among US youth by demographics and urbanization and to investigate trends by urbanization. Design, Setting, and Participants Measured weight and height among youth aged 2 to 19 years in the 2001-2016 National Health and Nutrition Examination Surveys, which are serial, cross-sectional, nationally representative surveys of the civilian, noninstitutionalized population. Exposures Sex, age, race and Hispanic origin, education of household head, and urbanization, as assessed by metropolitan statistical areas (MSAs; large: ≥ 1 million population). Main Outcomes and Measures Prevalence of obesity (body mass index [BMI] ≥95th percentile of US Centers for Disease Control and Prevention [CDC] growth charts) and severe obesity (BMI ≥120% of 95th percentile) by subgroups in 2013-2016 and trends by urbanization between 2001-2004 and 2013-2016. Results Complete data on weight, height, and urbanization were available for 6863 children and adolescents (mean age, 11 years; female, 49%). In 2013-2016, the prevalence among youth aged 2 to 19 years was 17.8% (95% CI, 16.1%-19.6%) for obesity and 5.8% (95% CI, 4.8%-6.9%) for severe obesity. Prevalence of obesity in large MSAs (17.1% [95% CI, 14.9%-19.5%]), medium or small MSAs (17.2% [95% CI, 14.5%-20.2%]) and non-MSAs (21.7% [95% CI, 16.1%-28.1%]) were not significantly different from each other (range of pairwise comparisonsP = .09-.96). Severe obesity was significantly higher in non-MSAs (9.4% [95% CI, 5.7%-14.4%]) compared with large MSAs (5.1% [95% CI, 4.1%-6.2%];P = .02). In adjusted analyses, obesity and severe obesity significantly increased with greater age and lower education of household head, and severe obesity increased with lower level of urbanization. Compared with non-Hispanic white youth, obesity and severe obesity prevalence were significantly higher among non-Hispanic black and Hispanic youth. Severe obesity, but not obesity, was significantly lower among non-Hispanic Asian youth than among non-Hispanic white youth. There were no significant linear or quadratic trends in obesity or severe obesity prevalence from 2001-2004 to 2013-2016 for any urbanization category (Prange = .07-.83). Conclusions and Relevance In 2013-2016, there were differences in the prevalence of obesity and severe obesity by age, race and Hispanic origin, and household education, and severe obesity was inversely associated with urbanization. Demographics were not related to the urbanization findings.